Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer Inc.    PFE

PFIZER INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

UK appoints vaccines minister to oversee COVID inoculations

11/28/2020 | 08:22am EST

LONDON — The British government appointed a vaccines minister on Saturday as it prepares to inoculate millions of people against the coronavirus, potentially starting within days.

Prime Minister Boris Johnson said Conservative lawmaker Nadhim Zahawi will oversee the country’s biggest vaccine program in decades.

The U.K. medicines regulator is currently assessing two vaccines — one developed by Pfizer and BioNTech, the other by Oxford University and AstraZeneca — to see if they are safe and effective. The Guardian newspaper reported that hospitals have been told they could receive the first doses of the Pfizer shot the week of Dec. 7, if it receives approval.

The U.K. says frontline health care workers and nursing home residents will be the first to be vaccinated, followed by older people, starting with those over age 80.

Britain has ordered 40 million doses of the Pfizer/BioNTech vaccine, enough for 20 million people, and 100 million doses of the Oxford/AstraZeneca vaccine.

In all, the U.K. government has agreed to purchase up to 355 million doses of vaccine from seven different producers, as it prepares to vaccinate as many of the country’s 67 million people as possible.

Decisions about which, if any, vaccines to authorize will be made by the independent Medicines and Healthcare Products Regulatory Agency.

Pfizer and BioNTech say their vaccine is 95% effective, according to preliminary data. It must be stored at ultra-cold temperatures of around minus 70 degrees Celsius (minus 94 Fahrenheit).

The Oxford-AstraZeneca vaccine can be stored at conventional refrigerator temperatures, and is also cheaper than its main rivals. But some scientists have questioned gaps in its reported results.

Oxford and AstraZeneca reported this week that their vaccine appeared to be 62% effective in people who received two doses, and 90% effective when volunteers were given a half dose followed by a full dose. They said the half dose was administered because of a manufacturing error, and they plan a new clinical trial to investigate the most effective dosing regimen.

The British government hopes a combination of vaccines and mass testing will end the need for restrictions on business and everyday life it imposed to curb the spread of the coronavirus. Britain has had Europe’s deadliest COVID-19 outbreak, with more than 57,000 confirmed virus-related deaths.

The prime minister said this week that officials hope to inoculate “the vast majority of the people who need the most protection by Easter.” But he warned that “we must first navigate a hard winter” of restrictions.

A four-week national lockdown in England is due to end Wednesday, and will be replaced by three-tiered system of regional measures that restrict business activity, travel and socializing. The vast majority of the country is being put into the upper two tiers.

The restrictions have sparked protests, with police arresting scores of people at an anti-lockdown demonstration in London on Saturday.

Several bottles and smoke bombs were thrown as anti-mask and anti-vaccine demonstrators scuffled with officers in the city's West End shopping district. The Metropolitan Police force said 155 people were arrested.

Johnson also faces opposition to the measures from dozens of his own Conservative Party’s lawmakers, who say the economic damage outweighs the public health benefits.

Bur Cabinet minister Michael Gove said the restrictions were “grimly” necessary to avoid the health system being overwhelmed this winter.

Writing in The Times of London, Gove said there are currently 16,000 coronavirus patients in British hospitals, not far below the April peak of 20,000. A rise in infections would mean coronavirus patients would “displace all but emergency cases. And then even those.," he said.

“If, however, we can keep the level of infection stable or, even better, falling, and hold out through January and February, then we can be confident that vaccination will pull the plug on the problem,” Gove wrote.

© 2020 The Canadian Press. All rights reserved., source Canadian Press DataFile

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -2.28% 7600 Delayed Quote.6.21%
BIONTECH SE -0.30% 105.97 Delayed Quote.29.99%
PFIZER INC. -2.87% 36.24 Delayed Quote.-1.55%
All news about PFIZER INC.
01:33aPRESS RELEASE : Evotec Starts Clinical Development of Chikungunya Antibody toget..
DJ
01/28PFIZER INC. : Ex-dividend day for
FA
01/27Pfizer Covid-19 Vaccine Works Against Mutations Found in U.K, South Africa Va..
DJ
01/27PFIZER : Tensions rise as AstraZeneca, EU spar over vaccine delays
AQ
01/27CELCUITY : Unveils Research Collaboration With Sarah Cannon Research Institute, ..
MT
01/27EU Clashes With AstraZeneca Over Covid-19 Vaccine Shortfall
DJ
01/27EU health official blasts slow vaccine delivery, and is consulting with Canad..
AQ
01/27Russia warns of delays in Sputnik V vaccine supply to Latin America
RE
01/27WHO Recommends Against Moderna, Pfizer Vaccines for Most Pregnant Women
DJ
01/27PFIZER : Canada scrambling for smaller syringes ahead of expected Pfizer vaccine..
AQ
More news
Financials (USD)
Sales 2020 46 470 M - -
Net income 2020 17 722 M - -
Net Debt 2020 43 412 M - -
P/E ratio 2020 14,0x
Yield 2020 4,02%
Capitalization 201 B 201 B -
EV / Sales 2020 5,27x
EV / Sales 2021 4,20x
Nbr of Employees 88 300
Free-Float 59,1%
Chart PFIZER INC.
Duration : Period :
Pfizer Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 41,71 $
Last Close Price 36,24 $
Spread / Highest target 46,2%
Spread / Average Target 15,1%
Spread / Lowest Target -0,66%
EPS Revisions
Managers and Directors
NameTitle
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Suzanne Nora Johnson Independent Director
Helen H. Hobbs Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC.-1.55%201 436
JOHNSON & JOHNSON6.67%441 951
ROCHE HOLDING AG3.62%309 011
NOVARTIS AG0.20%212 810
MERCK & CO., INC.-5.78%194 990
ELI LILLY AND COMPANY22.94%188 179